Citations

Clear

426 citation(s) found for "ST, Reza".

Abstract TH163: Persistence of Blood Pressure Reduction Following Renal Denervation Across Short, Medium, and Long Term Follow-Up
Rezasoltani, Mahsa , Namin, Sara Montazeri , Eshraghi, Reza , Bahrami, Ashkan , noroozi, matin, Akbari, Touba, Behbudi, Fatemeh, Mandegar, Mohammad Hossein , Yazdani, Mohammad Sepehr, Pirdehghan, Reza , Shahid, Farhan , Ebrahimi, Pouya , Namazi, Mohammad Javad , Moradi, Ali, noroozi, matin, Akbari, Touba, Yazdani, Mohammad Sepehr, Ahmed, Raheel

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.th163 Get It

Introduction: Resistant and uncontrolled hypertension pose persistent clinical and public health challenges. Renal denervation, a catheter-based procedure targeting renal sympathetic nerves, has emerged as a promising approach to lower blood pressure by reducing sympathetic overactivity. Hypothesis: A systematic review and meta-analysis of sham-controlled trials investigated whether renal denervation results in sustained blood pressure reduction across short-, medium-, and long-term follow-up. Methods: We searched PubMed, Embase, CENTRAL, and Web of Science through March 2025. The protocol was registered in PROSPERO (CRD420251015937). Randomized, sham-controlled trials of renal denervation in resistant/uncontrolled hypertension were included. Primary outcomes were ambulatory blood pressure (daytime, nighttime, and 24-hour); secondary outcomes included office and home blood pressure measurements. Follow-up durations were categorized into three groups: less than 6 months, 6–12 months, and greater than 12 months. Risk of bias was assessed using RoB-2. Results: Twenty trials (25 reports) with 2,167 RDN patients and 1,744 sham controls were included. Most trials had a low risk of bias. RDN significantly reduced 24-hour SBP (–3.29 mmHg, 95% CI: –5.91 to –0.67) and DBP (–1.42 mmHg, 95% CI: –2.29 to –0.55), despite high heterogeneity (I2 > 90%). Daytime DBP showed a significant reduction (–2.90 mmHg, 95% CI: –4.39 to –1.41), while other BP measures were less consistent. Home SBP was significantly reduced (–5.04 mmHg, 95% CI: –8.50 to –1.58). At 6–12 months, 24-hour SBP reduction persisted (–3.36 mmHg, 95% CI: –5.71 to –1.01), but DBP effects were nonsignificant. Long-term follow-up revealed nonsignificant changes in systolic blood pressure and diastolic blood pressure. Conclusions: Renal denervation modestly lowers BP in the short term (<6 months). Mid-term SBP reduction persists, but diastolic and long-term effects are inconsistent. These findings highlight the need for refined patient selection, optimized techniques, and longer follow-up trials.
Outcomes of patent foramen ovale closure in patients over 60 years with cryptogenic stroke: A systematic review and meta-analysis
Jazayeri, Seyed Behnam , Phan, Cattien , Ravichandran, Soumya , Maleki, Ana H., Dumitrașcu, Oana , Agrawal, Kunal , Modir, Royya , Hemmen, Thomas , Poli, Sven , Meyer, Dawn , Meyer, Brett C. , Modir, Royya , Poli, Sven , Meyer, Brett C , Ghozy, Sherief , Agrawal, Kunal, Zuern, Christine S. , Trabattoni, Daniela , Shahripour, Reza Bavarsad , Agrawal, Kush

Mayo Clinic

International Journal of Stroke | October 16, 2025 | Volume: 21 | Issue: 5 | Pages: 603-612

10.1177/17474930251392333 | PMID 41099439 Get It

Background: In younger patients (<60 years) with cryptogenic stroke (CS) presumed to be patent foramen ovale (PFO)-related, the standard approach involves transcatheter PFO closure combined with antithrombotic therapy. However, due to their exclusion from randomized clinical trials (RCTs), no formal recommendations exist for patients ⩾60 years. This study had two objectives (1) to compare the efficacy and safety of PFO closure versus antithrombotic therapy alone (ATA) exclusively in older patients (⩾60 years) and (2) to assess the outcomes of PFO closure in patients ⩾ 60 years versus < 60 years. Methods: We searched PubMed, Embase, Web of Science, and ScienceDirect databases to obtain articles in all languages from January 2004 until July 2025. The primary outcome was risk of recurrent stroke during follow-up. Secondary outcomes were risk of new-onset atrial fibrillation (AF), all-cause mortality, and in-hospital complications. PROSPERO registration ID: CRD420250652870. Results: Only one RCT (post hoc evaluation of the DEFENSE-PFO trial) and 11 observational studies were included. In patients aged ⩾ 60 years, risk of recurrent stroke was lower when PFO was closed compared with ATA (5.48% vs 10.05%, respectively, hazard ratio (HR) = 0.56, 95% confidence interval (CI) = 0.45–0.80, p < 0.001, I 2 = 45.6%). All-cause mortality was also lower for PFO closure versus ATA (1.73% vs 7.59%, respectively, HR = 0.41; 95% CI = 0.19–0.90, p = 0.02; I 2 = 43.8%). There was no difference between PFO closure and ATA in risk of new-onset AF (HR = 1.13, 95% CI = 0.53–2.44, p = 0.74). Compared with patients < 60 years, individuals ⩾ 60 years who underwent PFO closure had a higher risk of recurrent stroke (2.94% vs 1.04%, respectively, HR = 3.47; 95% CI = 1.61–7.48; p = 0.001), new-onset AF (4.86% vs 1.01%, respectively, HR = 4.12; 95% CI = 1.90–8.95; p < 0.001), and all-cause mortality during follow-up (8.32% vs 0.39%, respectively, HR = 8.24; 95% CI = 3.49–19.46; p < 0.0001). In-hospital complications after PFO closure were comparable between two age groups. Due to insufficient data, we were not able to perform a subgroup analysis based on anatomic features of PFO, antithrombotic regimen, or occluder devices. Conclusion: Based on available data, which is predominantly derived from observational studies, PFO closure is associated with a reduced risk of recurrent stroke compared to ATA in patients over 60 years. However, these findings are subjected to limitations, including the potential for selection bias, unmeasured confounding, and insufficient long-term follow-up. Furthermore, long-term randomized trials are essential to definitively confirm efficacy and establish clinical guidelines for PFO closure in this older population.
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices
Ibrahim, Ramzi , Abdelnabi, Mahmoud , Forst, Beani, Mee, Xuan Ci , Lim, Ghee Kheng, Bcharah, George , Barry, Timothy , Ayoub, Chadi , Arsanjani, Reza, Ibrahim, Ramzi , Pham, Hoang Nhat , Allam, Mohamed , Lim, Ghee Kheng, Farina, Juan M. , Arsanjani, Reza , Lee, Kwan

Mayo Clinic

ESC Heart Failure | October 14, 2025 | Volume: 12 | Issue: 6 | Pages: 4326-4335

10.1002/ehf2.15379 | PMID 41078121 Get It

Abstract Aims Left ventricular assist devices (LVADs) are a critical intervention for advanced heart failure (HF), serving as destination therapy or bridge to transplantation. Obesity and diabetes impact outcomes in patients with LVADs. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) demonstrate cardiovascular benefits; however, their role in patients with LVADs remains underexplored. We evaluated the association of GLP1-RA therapy with cardiovascular outcomes in patients with LVADs. Methods This retrospective cohort study used the TriNetX database, a research network database from 98 healthcare organizations. We queried for all adult LVAD recipients (≥18 years) and were stratified into GLP1-RA users and non-users. Propensity score matching (PSM) (1:1) balanced demographics, comorbidities, medication use and laboratory data. Outcomes included heart transplantation rates, heart failure hospitalizations, all-cause mortality, all-cause hospitalizations and cardiovascular events. Logistic regression models were used to estimate adjusted odds ratios (aOR). Results After PSM, we included a total of 1036 adult LVAD recipients (518 GLP1-RA users, 518 matched non-users) with a mean follow-up time of 311.6 ± 98.4 days for the GLP1-RA cohort and 304.0 ± 111.5 days for the non-GLP1-RAs cohort. Mean age was 56.7 ± 12.2 years in the GLP1-RA cohort and 58.0 ± 12.5 years in the non-GLP1-RA cohort. Females comprised 28.0% of both cohorts while White patients represented 52.1% of the GLP1-RA group and 53.1% of the non-GLP1-RA group. GLP1-RA users had higher heart transplantation rates [n = 98 (18.9%) vs. n = 44 (8.5%); aOR 2.514 (95% CI: 1.720–3.673)]. Acute HF events and all-cause hospitalizations were lower among GLP1-RA users compared with non-users [n = 288 (55.6%) vs. n = 357 (68.9%); aOR 0.565 (95% CI: 0.438–728) and n = 324 (62.5%) vs. n = 390 (75.3%); aOR 0.548 (95% CI: 0.420–0.716)]. No differences were observed when comparing the GLP1-RA cohort with the non-GLP1-RA cohort in regard to all-cause mortality [n = 32 (6.2%) vs. n = 44 (8.5%); aOR 0.709 (95% CI: 0.442–1.138)], stroke [n = 42 (8.1%) vs. n = 58 (11.2%); aOR 0.700 (95% CI: 0.461–1.062)] or cardiac arrest [n = 18 (3.5%) vs. n = 17 (3.3%); aOR 1.061 (95% CI: 0.541–2.082)]. Conclusions GLP1-RA therapy in patients with advanced HF and LVADs is potentially associated with improved heart transplantation rates while decreasing hospitalization and acute HF event rates.
Multidisciplinary Atrial Fibrillation Clinics: A Model for Comprehensive Management
Abdelnabi, Mahmoud , Ashour, Firas , Rodriguez, Cristian , Puchongmart, Chanokporn , Thiravetyan, Ben , Cruz, Diego , Ibrahim, Ramzi , Habib, Eiad , Kanaan, Christopher , Arsanjani, Reza, Sorajja, Dan , Ibrahim, Ramzi , Pham, Hoang Nhat , Arsanjani, Reza

Mayo Clinic

Reviews in Cardiovascular Medicine | October 11, 2025 | Volume: 26 | Issue: 9 | Pages: No page available

10.31083/rcm38739 | PMID 41089805 Get It

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity, mortality, and healthcare expenses. Meanwhile, effective management of AF requires a comprehensive, patient-centered approach that includes risk factor modification, rate and rhythm control strategies, and prevention of thromboembolic events. Multidisciplinary AF clinics have emerged as a model for comprehensive management to improve patient outcomes and reduce healthcare burden. This review discusses the rationale, structure, benefits, challenges, and future directions of multidisciplinary AF clinics, emphasizing their role in optimizing AF management.
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Analysis of Sex - Specific Cardiovascular Outcomes
Ibrahim, Ramzi , Al-Asmar, Rahmeh, AlHammouri, Hashim M. , Abdelnabi, Mahmoud , Forst, Beani, Sarkis, Patrick , Lester, Steven J., Rosenthal, Julie , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Pham, Hoang Nhat , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Current Cardiology Reviews | October 6, 2025 | Volume: 22 | Issue: 4 | Pages: No page available

10.2174/011573403x394902250911111958 | PMID 41047672 Get It

Introduction: Sex-based differences in outcomes among patients with heart failure with reduced ejection fraction (HFrEF) treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain underexplored. This study aimed to evaluate sex-specific differences in cardiovascular outcomes in patients with HFrEF receiving SGLT2 inhibitors alongside guidelinedirected medical therapy (GDMT). Methods: We conducted a retrospective cohort study using the TriNetX global research network. Adults with HFrEF treated with SGLT2is and GDMT were stratified by sex. Propensity score matching (PSM) was used to balance baseline demographics, comorbidities, medications, and laboratory data. Primary outcomes were all-cause mortality and acute heart failure (HF) events; secondary outcomes included hospitalizations, arrhythmias, renal outcomes, and advanced therapies. Results: After PSM, 17,408 male and 17,408 female patients were analyzed. Male patients had lower odds of acute HF events (aOR: 0.949; 95% CI: 0.909–0.991), all-cause hospitalizations (aOR: 0.933; 95% CI: 0.895–0.973), and renal failure (aOR: 0.915; 95% CI: 0.870–0.962). No significant differences were observed in all-cause mortality (aOR: 1.003; 95% CI: 0.926–1.087) or heart transplantation, although LVAD use was more frequent in males (aOR: 1.416; 95% CI: 1.053–1.905). Discussion: The findings highlighted potential sex-based disparities in outcomes for patients with HFrEF on SGLT2is. Differential prescribing patterns, comorbidity burden, or timing of therapy initiation may contribute to observed differences. Conclusion: Among HFrEF patients treated with SGLT2is, males experienced lower risks of HF events, hospitalizations, and renal failure compared to females, despite similar mortality. Further research is needed to understand and address sex-specific disparities in HFrEF management.
In reply: Consideration of possible involvement of oxidation of Lp(a) in the association between Lp(a) and atrial fibrillation
Ayoub, Chadi , Arsanjani, Reza , Ayoub, Chadi , Arsanjani, Reza , Awad, Kamal

Mayo Clinic

European Journal of Preventive Cardiology | September 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf590 | PMID 40991733 Get It

Angiotensin II receptor blockers and isolated left bundle branch block: A retrospective cohort analysis
Said, Nada, Ibrahim, Ramzi , Bcharah, George , Abdelnabi, Mahmoud , Habib, Eiad , Ibrahim, Ramzi , Pham, Hoang Nhat , Arsanjani, Reza

Mayo Clinic

Journal of Investigative Medicine | September 18, 2025 | Volume: 74 | Issue: 4 | Pages: 399-401

10.1177/10815589251366917 | PMID 40964832 Get It

Chronic left bundle branch block (LBBB) has been associated with adverse cardiac remodeling and the development of cardiomyopathy. This retrospective cohort study evaluated the impact of angiotensin II receptor blocker (ARB) therapy on cardiovascular outcomes in adults with isolated LBBB with no known heart failure (HF), cardiomyopathy, or ischemic heart disease. Using the TriNetX global research network, patients were stratified by ARB use and followed for up to 5 years. Propensity score matching was performed to balance characteristics. Three thousand two hundred sixty-six patients were included in each group with comparable baseline characteristics. The ARB therapy was not associated with a reduction in new-onset acute HF events (4.9% vs 4.4%; hazard ratio (HR) 1.05 (95% CI 0.84–1.32)). Similarly, there were no significant differences in rates of all-cause hospitalizations, cardiac arrest, or ventricular tachycardia. However, ARB use was associated with a significantly lower, all-cause mortality rate (8.6% vs 12.1%; HR 0.67 (95% CI 0.57–0.77)). This is the first real-world study examining ARB use in a cohort with isolated LBBB, highlighting a potential mortality benefit, despite no difference in acute HF risk. While ARBs are not effective in preventing LBBB-induced cardiomyopathy based on these findings, the observed survival advantage warrants further investigation. Prospective studies are needed to elucidate mechanisms underlying this mortality benefit and to determine whether ARBs should be considered in the management of patients with isolated LBBB.
A structured training curriculum for robot‐assisted radical nephroureterectomy: a Delphi consensus study
Sayyid, Rashid K. , Wu, Zhenjie , Antonelli, Alessandro , Guo, Shengjie , Hung, Andrew J. , Ma, Lulin , Margulis, Vitaly , Mehrazin, Reza , Porter, James , Potretzke, Aaron M. , Seisen, Thomas , Stein, Robert J. , Wang, Long , Wu, Jitao, Xylinas, Évanguelos , Djaladat, Hooman , Sayyid, Rashid K , Wu, Zhenjie , Abdollah, Firas , Antonelli, Alessandro , Ma, Lulin , Margulis, Vitaly , Matin, Surena F. , Potretzke, Aaron, Simone, Giuseppe , Wang, Long , Autorino, Riccardo , Djaladat, Hooman , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Ghoreifi, Alireza , Abdollah, Firas , Eun, Daniel , Ma, Lulin , Pradère, Benjamin , Rouprêt, Morgan , Shariat, Shahrokh F. , Simone, Giuseppe , Yao, Lin Xin , Zargar, Homayoun S. , Autorino, Riccardo , Cacciamani, Giovanni

Mayo Clinic

BJU International | September 17, 2025 | Volume: 136 | Issue: 6 | Pages: 1114-1120

10.1111/bju.70000 | PMID 40960222 Get It

Objectives To develop an internationally validated, structured robot‐assisted radical nephroureterectomy (RARNU) training programme through expert consensus. Materials and Methods A RARNU‐specific questionnaire was developed/adapted from previously published, validated questionnaires for robot‐assisted urological procedures. This included five key domains and 11 surgical steps. In all, 30 upper tract urothelial carcinoma experts were invited to participate. A two‐stage modified Delphi approach was employed. Consensus was defined as ≥80% agreement. Modifications and additional statements were proposed during the second round following qualitative/quantitative feedback from the initial round. Results Response rates for the first and second Delphi rounds were 80% (24/30) and 92% (22/24), respectively. All agreed that adoption of a standardised training curriculum can improve clinical outcomes during the RARNU learning curve. There was ≥92% agreement on all proposed RARNU steps. Five RARNU clinical modules of increasing complexity were defined using individual step difficulty and number of prior RARNU cases required, with ≥96% agreement among respondents. Respondents unanimously agreed that the final assessment should be based on a procedure‐specific scale focusing on the hilar dissection, ureteric dissection, and bladder cuff excision steps. No consensus was reached for the annual minimum RARNU volume required for eligibility as a RARNU curriculum host centre. Conclusion This is the first structured training curriculum for RARNU using international expert consensus. This will help guide surgical educators and trainees toward independent completion of a full RARNU.
Humanized anti-P2X4 scFv reduces ATP-induced P2X4 currents and modulates excitability in human DRG neurons
Zurek, Nesia A. , Shilling, Mark , Demeter, Jenna B. , Ehsanian, Reza , Adams, Ian M. , Séguéla, Philippe , Alles, Sascha R.A. , Kunamneni, Adinarayana , Westlund, Karin N , Alles, Sascha Ra , Goins, Aleyah E. , Goyal, Sachin , Peña, June Bryan de la , Westlund, Karin N.

Mayo Clinic

Molecular Pain | August 26, 2025 | Volume: 21 | Issue: No issue available | Pages: No page available

10.1177/17448069251376200 | PMID 40856314 Get It

Chronic pain affects nearly 100 million adults in the U.S., yet few novel therapeutics have emerged in recent decades. P2X4 receptor (P2X4R), implicated in pain signaling, represents a promising target. We evaluated a humanized single-chain variable fragment (hscFv) targeting P2X4R for its ability to reduce ATP-induced currents and modulate excitability in human dorsal root ganglion (hDRG) neurons. Voltage-clamp recordings confirmed that human P2X4R (hP2X4R) hscFv significantly reduced ATP-evoked currents in HEK-293T cells expressing human P2X4, likely by relocalization of the receptor to the perinuclear region after hscFv treatment. Immunohistochemistry and transcriptomic analyses demonstrated widespread P2X4R ( P2RX4 ) expression across hDRG neuronal subtypes in both male and female donors. Current-clamp recordings revealed that hP2X4R hscFv selectively increased action potential (AP) threshold in multi-firing hDRG neurons, without affecting single-firing neurons. Spontaneous activity at rest and depolarizing spontaneous fluctuation (DSF) amplitude were also reduced. Analysis confirmed consistent effects of hP2X4R hscFv on excitability parameters. These findings suggest that hP2X4 hscFv exerts modest but targeted effects on human sensory neurons, supporting its potential as a novel therapeutic for chronic pain.